End of Day Message

LONDON, 07 Oct. 2025 (GLOBE NEWSWIRE) -- This is the End of Day Message for GlobeNewswire.

GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information provider.

Disclaimer

The content and accuracy of all information distributed through Notified is wholly the responsibility of the originator. Notified accepts no liability for any losses arising from reliance by any person upon the content of any announcement.

If you have any questions about this message, please Contact Us.

You May Also Be Interested In

•  Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
• New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States